Antiemetics
Key Points
Key Points
- The development of increasingly effective antiemetic regimens over the last quarter century has greatly reduced the incidence of nausea and vomiting due to chemotherapy.
- The recommended approach to preventing nausea and vomiting varies by the emetic risk of the treatment regimen.
- Adherence to antiemetic guidelines has been linked with improved control of nausea and vomiting.
- This update of the 2017 guideline adds guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).
Treatment
...atment
...t Patients...
Note: For adult patients, the addition...
...gh-Emetic-Risk Antineoplastic Age...
...t patients treated with cisplatin and ot...
...ts treated with an anthracycline combine...
...oderate-Emetic-Risk Antineoplastic Agen...
...patients treated with carboplatin area under th...
...ts treated with moderate-emetic-risk...
...lt patients treated with cyclophosphamide, doxor...
...metic-Risk Antineoplastic Agents...
...ts treated with low-emetic-risk antin...
...metic Risk Antineoplastic Agents...
...tients treated with minimal emetic risk antineo...
...ineoplastic Combinations...
...tients treated with antineoplastic combi...
...djunctive Drugs
...pam is a useful adjunct to antiemetic drugs,...
...nnabinoids
...ence remains insufficient for a recommendation reg...
...omplementary and Alternative T...
...mains insufficient for a recommendation for or a...
...otherapy With Stem-Cell or Bone Marrow T...
...ents treated with high-dose chemotherapy...
...ug combination of an NK1 receptor antagonist,...
...ay Antineoplastic Therapy...
...lt patients treated with multiday antine...
...tients treated with 4- or 5-day cisplatin regimens...
...hrough Nausea and Vomit...
...ents with breakthrough nausea or vomit...
...lt patients who experience nausea or vomiting des...
...inol and nabilone ( IC , I , M )6539...
...ise ( IC , L , M )6539...
...ry Nausea and Vomiting...
...ts should receive the most active antie...
...ic Risk Radiation Therap...
...s treated with high-emetic-risk radia...
...tic Risk Radiation Therapy...
...ult patients treated with moderate-emetic-...
...Risk Radiation Therapy
...ts treated with radiation therapy to the br...
...ic Risk Radiation Therapy...
Adult patients treated with minimal emeti...
...Radiation and Antineoplastic Agent Therapy...
...ients treated with concurrent radiation and an...
...ediatric Patients
High Emetic Risk Antineop...
(Updated) Pediatric patients treated...
...iatric patients treated with high-emetic...
...atric patients treated with high-emetic-risk antin...
...Emetic Risk Antineoplastic Agents...
Pediatric patients treated with moderate-emetic-ri...
...diatric patients treated with moder...
...w Emetic Risk Antineoplasti...
...ents treated with low-emetic-risk antine...
...al Emetic Risk Antineoplastic Agents
...ts treated with minimal emetic risk antineopl...
...Risk of Single Intravenous Antineoplastic...
...Risk of Single Oral Antineoplastic Ag...
...iemetic Dosing for Adults by Chemotherapy Risk...
...ic Risk in Adults by Site of Radiation Therap...
...tic Administration in Adults by Radiat...